The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPORE

描述 3 总体评论 3 孢子囊组织和能力 6 科学合作 8 人类受试者保护 10 脊椎动物 10 科学审评员注释 10 个人项目和核心 11 项目1： 低外显率基因与甲状腺乳头状癌的易感性 11 项目二： 放射性碘治疗后唾液腺功能的保护 甲状腺癌 15 项目3： 发展甲状腺髓样癌的综合治疗 23 项目4： 新型循环甲状腺髓样癌标志物的开发和验证 29 核心A/1： 综合临床病理学和生物库核心 34 核心B/2： 生物统计学核心 38 核心C/3： 行政核心 41 企业文化 43 职业发展计划 45 委员会的预算建议 48 特别强调小组名册 描述（由申请人提供）：俄亥俄州州立大学/医学博士的主要目标。安德森甲状腺癌孢子是改善结果和甲状腺癌患者的生活，通过识别遗传"风险"的个人，允许早期诊断和预测 研究肿瘤行为，开发新的方法来最大限度地减少治疗的副作用，并为进行性转移性疾病开发更好的生物标志物和治疗方案。有几个因素支持将这些努力应用于甲状腺癌的重要性：1）甲状腺癌的发病率在美国和世界范围内以所有恶性肿瘤中最快的速度上升;它现在是女性中第五常见的恶性肿瘤，男性中第11常见。2)甲状腺癌通常采取无痛过程，因此随着发病率的增加，长期存活的个体群体不断扩大（约500，000人），其中许多人遭受初始治疗的终身影响。3)对于侵袭性更强的甲状腺癌（例如髓样癌（MTC））患者来说，目前还没有治愈性疗法或生物标志物可以准确预测疾病的结果或对特定治疗的反应，从而限制了个性化治疗强度的努力。为了实现我们的目标，此SPORE应用程序建议支持来自该领域两个具有合作临床试验历史的领先机构的经验丰富的研究人员组成的多机构团队。我们选择了以下四个项目来关注甲状腺癌患者快速转化为临床实践的关键领域：1）甲状腺乳头状癌易感基因的低表达; 2）甲状腺癌患者放射性碘诱导唾液腺损伤的生物标志物发现和个性化干预; 3）甲状腺髓样癌的联合治疗;和4）新的循环甲状腺髓样癌标志物的开发和验证。通过这些转化项目，以及职业发展和发展研究计划，我们的目标是影响甲状腺癌临床管理的关键领域。 相关性：甲状腺癌的发病率正在上升。临床护理中的关键问题涉及对更具侵袭性疾病的预测性检测，提高生存率，因为许多患者在诊断后存活数十年，改善侵袭性甲状腺癌患者的治疗，改善转移的检测和监测。

DESCRIPTION 3 OVERALL CRITIQUE 3 SPORE PROGRAM ORGANIZATION AND CAPABILITIES 6 SCIENTIFIC COLLABORATIONS 8 PROTECTION OF HUMAN SUBJECTS 10 VERTEBRATE ANIMALS 10 SCIENTIFIC REVIEW OFFICER'S NOTES 10 INDIVIDUAL PROJECTS AND CORES 11 PROJECT 1: Low-Penetrance Genes in the Predispositon to Papillary Thyroid Cancer 11 PROJECT 2: Preserving Salivary Gland Function after Radioiodine Therapy for Thyroid Cancer 15 PROJECT 3: Developing Combination Therapies for Medullary Thyroid Cancer 23 PROJECT 4: Development and Validation of Novel Circulating Medullary Thyroid Cancer Markers 29 CORE A/1: Integrated Clinicopathology and Biorespository Core 34 CORE B/2: Biostatistics Core 38 CORE C/3: Administrative Core 41 DEVELOPMENTAL RESEARCH PROGRAM 43 CAREER DEVELOPMENT PROGRAM 45 COMMITTEE BUDGET RECOMMENDATIONS 48 SPECIAL EMPHASIS PANEL ROSTER DESCRIPTION (provided by applicant): The primary goal of The Ohio State University / M.D. Anderson Thyroid Cancer SPORE is to improve the outcomes and lives of patients with thyroid cancer by identifying genetically "at-risk" individuals allowing for early diagnosis and prediction of tumor behavior, developing new approaches to minimize side effects of treatments, and developing better biomarkers and treatment options for progressive metastatic disease. Several factors support the importance of applying these efforts to thyroid cancer: 1) Thyroid cancer incidence is rising at the fastest rate of all malignancies in the United States and worldwide; it s now the 5th most common malignancy in women and 11th most common in men. 2) Thyroid cancer typically takes an indolent course, thus with the increasing incidence there is an ever enlarging population of individuals (-500,000) surviving long term, many of whom suffer from lifelong effects of initial therapy. 3) For patients with more aggressive forms of thyroid cancer, such as medullary cancer (MTC), there exist no curative therapies or biomarkers that accurately predict outcome from disease or response to particular treatments thereby limiting efforts to individualize therapeutic intensity. In order to achieve our goals, this SPORE application proposes to support a multi-institutional team of experienced investigators from two of the leading institutions in the field with a history of collaborative clinical trials. We have chosen t focus on critical areas of need for rapid translation into clinical practice for thyroid cancer patients with the following four Projects supported by outstanding Cores: 1) Low-penetrance genes in the predisposition to papillary thyroid carcinoma; 2) Biomarker discovery and personalized intervention of radioiodine induced salivary gland damage in thyroid cancer patients; 3) Developing combination therapies for Medullary Thyroid Cancer; and 4) Development and validation of novel circulating medullary thyroid cancer markers. Through these translational Projects, as well as Career Developmental and Developmental Research Programs, we aim to impact on critical areas of need in thyroid cancer clinical management for all forms of thyroid cancer. RELEVANCE: Thyroid cancer incidence is rising. Key issues in clinical care related to predictive testing for more aggressive disease, improving survivorship as many patients live for decades after their diagnosis, improving treatment for patients with aggressive forms of thyroid cancer and improving detection and monitoring of metastases This SPORE addresses these critical areas to improve the outcomes of patients with thyroid cancer.